PDF(Pubmed)
Abstract：
The Korean Association of Urogenital Tract Infection and Inflammation and the Korea Disease Control and Prevention Agency regularly update, revise, and develop new content for the Korean sexually transmitted infection (STI) guidelines. These professional bodies respond to changing epidemiological trends and evolving scientific evidence, and consider advances in laboratory diagnostics and research. The principal recommendations of the 2023 Korean STI guidelines in terms of viral infection follow: 1) If genital herpes recurs more than 4-6 times annually, suppressive therapy with acyclovir 400 mg orally 2 times/day or famciclovir 250 mg orally 2 times/day or valacyclovir 500 mg orally once a day (for patients with <10 episodes/year) or valacyclovir 1 g orally once daily (for patients with ≥10 episodes/year) is recommended to prevent recurrence; 2) molecular human papillomavirus (HPV) testing is not recommended as a routine test for STI status, nor for determination of HPV vaccination status; and 3) patients should inform their current sexual partners about anogenital warts because the types of HPV that cause such warts can be passed to partners. These guidelines will be updated every 5 years and will be revised when new knowledge on STIs becomes available and there is a reasonable need to improve the guidelines. Physicians and other healthcare providers can use the guidelines to assist in the prevention and treatment of STIs.
摘要：
韩国泌尿生殖道感染和炎症协会和韩国疾病控制和预防机构定期更新，修改,并为韩国性传播感染（STI）指南开发新内容。这些专业机构应对不断变化的流行病学趋势和不断发展的科学证据，并考虑实验室诊断和研究的进展。2023年韩国性传播感染指南在病毒感染方面的主要建议如下：1）如果生殖器疱疹每年复发超过4-6次，推荐使用阿昔洛韦400mg口服2次/天或泛昔洛韦250mg口服2次/天或伐昔洛韦500mg口服1次/天（<10次/年）或伐昔洛韦1g口服1次/天（≥10次/年）进行抑制治疗，以防止复发；2）不建议将分子人乳头瘤病毒（HPV）检测作为STI状态的常规检测，也不用于确定HPV疫苗接种状态；3）患者应告知其现有性伴侣有关肛门生殖器疣的信息，因为导致此类疣的HPV类型可以传递给伴侣。这些指南将每5年更新一次，并在获得有关性传播感染的新知识并且有必要改进指南时进行修订。医生和其他医疗保健提供者可以使用该指南来协助预防和治疗性传播感染。
